News
Video
Long-term Options for IgAN Management, with Jonathan Barratt, MD, PhD
Author(s):
Key Takeaways
- IgA nephropathy management is evolving with new pharmacotherapies, improving patient prognosis significantly.
- Nefecon demonstrates effective proteinuria reduction over nine months, with similar results upon re-dosing after a 15-month break.
In this segment, Barratt reflects on recent updates in the management of IgA nephropathy, particularly data on long-term use of Nefecon.
The management of IgA nephropathy (IgAN) is in the midst of revolutionary change. Driven by advances in pathophysiology occurring over the course of several decades, these changes have led to the emergence of several new pharmacotherapies within the pipeline. Now, with multiple fully approved therapies, the prognosis for patients is brighter than at any point in history.
In this video, which is the third in a 5-part series, Barratt highlights the significance of the open-label extension study on Nefecon for IgA nephropathy, noting it addresses crucial questions about long-term treatment and re-dosing. While Nefecon showed efficacy over a nine-month treatment followed by a 15-month break, Barratt points out that many young patients will require guidance for extended use.
This new data shows that re-dosing Nefecon yields a similar proteinuria reduction to the initial course without compromising safety, providing reassurance for clinicians. Moreover, even patients initially on placebo responded similarly upon subsequent treatment, despite progressing further in their disease course. According to Barratt, he findings are vital for nephrologists seeking to implement repeat Nefecon treatment effectively for sustained patient outcomes.
Relevant disclosures of interest for Barratt included Argenx, Calliditas Therapeutics, Chinook Therapeutics, Galapagos NV, GSK, Novartis, and Travere Therapeutics.
